Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingolf Cascorbi

Showing results (21-30 of 192) with videos related to

Pageof 20
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|August 28, 2014
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevanceOliver Bruhn, Ingolf Cascorbi
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Germline variants in cancer therapyMeike Kaehler, Ingolf Cascorbi
Epigenomics|August 28, 2012
miRNAs as mediators of drug resistanceSierk Haenisch, Ingolf Cascorbi
Handbook of Experimental Pharmacology|March 7, 2023
Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid LeukemiaMeike Kaehler, Ingolf Cascorbi
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2021
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?Henrike Bruckmueller, Ingolf Cascorbi
Clinical Pharmacology and Therapeutics|July 19, 2021
Drug-Drug-Gene Interactions: A Call for Clinical ConsiderationHenrike Bruckmueller, Ingolf Cascorbi
Expert Opinion on Drug Metabolism & Toxicology|May 29, 2024
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinolAnne Kasten, Ingolf Cascorbi
Pharmacological Research|October 15, 2020
Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactionsCharles Awortwe, Ingolf Cascorbi
Deutsches Arzteblatt International|November 25, 2025
Metamizole: Indications and RisksIngolf Cascorbi, Ralf Baron
Clinical Pharmacology and Therapeutics|May 19, 2025
Deciphering the Relative Contribution of CYP3A4 Versus P-Glycoprotein for the Shared Substrate Cyclosporine-Commentary on Lown et alIngolf Cascorbi, Richard B Kim
Pageof 20

Showing results (21-30 of 192) with videos related to

Sort By:
Pageof 20
Expert Opinion on Drug Metabolism & Toxicology|August 28, 2014
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevanceOliver Bruhn, Ingolf Cascorbi
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Germline variants in cancer therapyMeike Kaehler, Ingolf Cascorbi
Epigenomics|August 28, 2012
miRNAs as mediators of drug resistanceSierk Haenisch, Ingolf Cascorbi
Handbook of Experimental Pharmacology|March 7, 2023
Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid LeukemiaMeike Kaehler, Ingolf Cascorbi
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2021
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?Henrike Bruckmueller, Ingolf Cascorbi
Clinical Pharmacology and Therapeutics|July 19, 2021
Drug-Drug-Gene Interactions: A Call for Clinical ConsiderationHenrike Bruckmueller, Ingolf Cascorbi
Expert Opinion on Drug Metabolism & Toxicology|May 29, 2024
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinolAnne Kasten, Ingolf Cascorbi
Pharmacological Research|October 15, 2020
Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactionsCharles Awortwe, Ingolf Cascorbi
Deutsches Arzteblatt International|November 25, 2025
Metamizole: Indications and RisksIngolf Cascorbi, Ralf Baron
Clinical Pharmacology and Therapeutics|May 19, 2025
Deciphering the Relative Contribution of CYP3A4 Versus P-Glycoprotein for the Shared Substrate Cyclosporine-Commentary on Lown et alIngolf Cascorbi, Richard B Kim
Pageof 20